Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candidate lifileucel for recurrent, metastatic, or persistent cervical cancer; and C-145-03, of its product candidate LN-145, for recurrent and/or metastatic head and neck squamous cell carcinoma. Iovance Biotherapeutics, Inc. has collaborations and licensing agreements with H. Lee Moffitt Cancer Center; M.D. Anderson Cancer Center; Ohio State University; Centre hospitalier de l'Université de Montreal; Cellectis S.A.; and Novartis Pharma AG. The company was formerly known as Lion Biotechnologies, Inc. and changed its name to Iovance Biotherapeutics, Inc. in June 2017. Iovance Biotherapeutics, Inc. was incorporated in 2007 and is headquartered in San Carlos, California.

Iovance Biotherapeutics, Inc.

Iovance Biotherapeutics (NASDAQ: IOVA) aims to be the global leader in innovating, developing and delivering tumor infiltrating lymphocyte (TIL) therapies for patients with cancer. We are pioneering a transformational approach to cure cancer by harnessing the human immune system’s ability to recognize and destroy diverse cancer cells in each patient. Our lead late-stage TIL product candidate, lifileucel for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors. We are committed to continuous innovation in cell therapy, including gene-edited cell therapy, that may extend and improve life for patients with cancer.

We are adding to our talented team as we actively prepare for our initial commercial launch, advance our research and development efforts, and build our internal manufacturing capabilities. Iovance is headquartered in the San Francisco Bay Area. Our Iovance Cell Therapy Center (iCTC), a state-of-the-art manufacturing facility, is located in Philadelphia. We also have a research site in Tampa, Florida. 

Any information expressed by Iovance is subject to the risk factors and information on forward-looking statements contained in its filings with the Securities and Exchange Commission and available here: https://ir.iovance.com/sec-filings 


Broadfin Capital

OrbiMed

Quogue Capital

Frazier Healthcare Partners

We're proud to share that the @US_FDA
 has granted accelerated approval for our therapy for advanced melanoma.
Learn more: https://lnkd.in/etxeMZUK

Today Iovance reported fourth quarter and full year 2023 financial results and corporate updates. We will host an audio webcast at 4:30 pm ET, please join us for the live webcast or listen to the replay: https://lnkd.in/dDyHAfWs 

We recently became aware of a phishing scam targeting potential applicants with fraudulent job offers. Please be advised that Iovance will never ask you to download a messaging app, provide personal information via text message, or require any financial commitment during the recruitment process. For more information on how to spot a job scam, please visit: https://lnkd.in/ee-QjXfX.

	Dec '13	Dec '14	Dec '15	Dec '16	Dec '17	Dec '18	Dec '19	Dec '20	Dec '21	Dec '22	Dec '23
revenue											1.19M -
cost of revenue	4.66M -	9.34M 100.55%					8.12M -	8.71M 7.25%	13.98M 60.47%	21.14M 51.18%	33.13M 56.74%
gross profit	-4.66M -	-9.34M 100.55%					-8.12M -	-8.71M 7.25%	-13.98M 60.47%	-21.14M 51.18%	-31.94M 51.11%
selling and marketing expenses
general and administrative expenses	4.66M -	9.34M 100.55%	12.39M 32.72%	25.60M 106.63%	21.26M 16.95%	28.43M 33.71%	40.85M 43.68%	60.21M 47.40%	83.66M 38.95%	104.10M 24.42%
selling general and administrative expenses	4.66M -	9.34M 100.55%	12.39M 32.72%	25.60M 106.63%	21.26M 16.95%	28.43M 33.71%	40.85M 43.68%	60.21M 47.40%	83.66M 38.95%	104.10M 24.42%	84.54M 18.78%
research and development expenses	1.33M -	2.70M 103.45%	15.47M 471.99%	28.04M 81.23%	71.61M 155.43%	99.83M 39.40%	166.02M 66.31%	201.73M 21.51%	259.04M 28.41%	294.78M 13.80%	344.08M 16.72%
other expenses	16.66M -
cost and expenses	22.64M -	12.04M 46.82%	27.86M 131.39%	53.64M 92.53%	92.88M 73.15%	128.26M 38.09%	206.87M 61.29%	261.94M 26.62%	342.70M 30.83%	398.88M 16.39%	461.75M 15.76%
operating expenses	22.64M -	12.04M 46.82%	27.86M 131.39%	53.64M 92.53%	92.88M 73.15%	128.26M 38.09%	206.87M 61.29%	261.94M 26.62%	342.70M 30.83%	398.88M 16.39%	428.62M 7.46%
interest expense	444.73K -	5.66K 98.73%	200K 3,433.57%							2.98M -
ebitda	-22.63M -	-11.95M 47.19%	-27.86M 133.10%	-53.64M 92.53%	-92.88M 73.15%	-128.26M 38.09%	-206.87M 61.29%	-260.80M 26.07%	-342.70M 31.41%	-398.88M 16.39%	-427.43M 7.16%
operating income	-22.64M -	-12.04M 46.82%	-27.86M 131.39%	-53.64M 92.53%	-92.88M 73.15%	-128.26M 38.09%	-206.87M 61.29%	-261.94M 26.62%	-342.70M 30.83%	-398.88M 16.39%	-460.56M 15.46%
depreciation and amortization	7.09K -	88.22K 1,144.83%	999K 1,032.38%	978K 2.10%	952K 2.66%	956K 0.42%	1.17M 22.28%	1.14M 2.48%	13.98M 1,126.32%	21.14M 51.18%	33.13M 56.74%
total other income expenses net	-2.30M -	5.66K 100.25%	200K 3,433.57%	745K 272.50%	813K 9.13%	4.68M 475.40%	9.32M 99.14%	2.36M 74.71%	451K 80.86%	2.98M 561.86%	13.04M 336.95%
income before tax	-25.38M -	-12.03M 52.58%	-27.66M 129.84%	-52.89M 91.23%	-92.06M 74.05%	-123.58M 34.23%	-197.56M 59.86%	-259.58M 31.40%	-342.25M 31.85%	-395.89M 15.67%	-447.52M 13.04%
income tax expense	444.73K -		-999K -	-978K 2.10%	-952K 2.66%	4.68M 591.39%	-10.48M 324.13%	-2.36M 77.53%	-14.43M 512.52%	-5.97M 58.63%	-3.48M 41.73%
net income	-25.38M -	-12.03M 52.58%	-27.66M 129.84%	-52.89M 91.23%	-92.06M 74.05%	-123.58M 34.23%	-187.07M 51.38%	-257.23M 37.50%	-327.82M 27.45%	-389.92M 18.94%	-444.04M 13.88%
weighted average shs out	9.76M -	24.99M 155.94%	44.41M 77.74%	55.27M 24.45%	65.24M 18.05%	97.28M 49.10%	124.34M 27.82%	138.30M 11.23%	153.41M 10.92%	159.26M 3.82%	235.13M 47.64%
weighted average shs out dil	9.76M -	24.99M 155.94%	44.41M 77.74%	55.27M 24.45%	65.24M 18.05%	97.28M 49.10%	124.34M 27.82%	138.30M 11.23%	153.41M 10.92%	159.26M 3.82%	235.13M 47.64%
eps	-2.60 -	-0.48 81.54%	-0.62 29.17%	-0.96 54.84%	-1.41 46.87%	-1.27 9.93%	-1.50 18.11%	-1.86 24.00%	-2.14 15.05%	-2.45 14.49%	-1.89 22.86%
epsdiluted	-2.60 -	-0.48 81.54%	-0.62 29.17%	-0.96 54.84%	-1.41 46.87%	-1.27 9.93%	-1.50 18.11%	-1.86 24.00%	-2.14 15.05%	-2.45 14.49%	-1.89 22.86%

NASDAQ:IOVA

Iovance Biotherapeutics, Inc.

Last Close

10.43

17/05 20:00

Market Cap

1.94B

Beta: 0.20

Volume Today

4.45M

Avg: 3.51M

PE Ratio

−4.56

PFCF: −7.39